Send PM
Followers 25
Posts 2400
Boards Moderated 1
Alias Born 10/24/2015

FREE
IPSC REPORT

Re: NY1972 post# 14

Sunday, 08/28/2022 2:54:02 PM

Sunday, August 28, 2022 2:54:02 PM

Post# of 26
Dr. Kaufman has presented some preclinical data


As for clinical, that comes from FATE and NKTX (using healthy donor), even though there are some differences between the programs in the same indications. From memory, in R/R NHL, FATE's best efficacy was achieved at a (much) lower dose (+/- rituximab), while NKTX had to go up to a billion across three doses (no rituximab).

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPSC News